TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have participated and discontinued in the previous PAH placebo controlled study due to clinical worsening on placebo or tadalafil 2.5 mg, 10mg, or 20 mg~* Must have completed Week 16 of the previous PAH study and had either no clinical worsening or became clinically worse at the Week 16 visit on placebo or tadalafil 2.5 mg, 10mg, or 20 mg~* Females who have a negative urine pregnancy test and are willing to use 2 types of birth control~* Be 12 years or older (country specific regulations apply) with parental approval~Exclusion Criteria:~* Participated in the placebo controlled study and had clinical worsening on 40 mg tadalafil~* Have left-sided heart disease~* Have a musculoskeletal disorder that limits being able to get around~* Nitrate use~* Certain current systemic treatments

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 20 mg tadalafil (Type: ACTIVE_COMPARATOR): 20 milligram (mg) tadalafil taken once a day
- 40 mg tadalafil (Type: ACTIVE_COMPARATOR): 40 mg tadalafil tablet taken once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Macular edema~* Received at least 2 OZURDEX® injections~Exclusion Criteria:~* Received OZURDEX® injections as part of a clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Participants (Type: None): Patients who received at least 2 injections of OZURDEX® (dexamethasone intravitreal implant) to treat Macular Edema.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vorapaxar in the Human Endotoxemia Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~  * ≥60 kg bodyweight~ * Normal findings in medical history and physical examination unless the investigator considers the abnormality to be clinically irrelevant~ * Normal laboratory values unless the investigator considers abnormalities to be clinically irrelevant~ * Willingness to comply with the trial's safety demands (to refrain from excessive sporting activities two weeks after Vorapaxar intake, i.e. full contact sports, climbing, mountain biking etc.)~ * Ability to understand the purpose and nature of the study, as well as the associated risks No planned surgeries or other medical interventions in the planned study period~Exclusion Criteria:~* Intake of any drugs that may interfere with the trial's endpoints or drugs (i.e. platelet inhibitors, anticoagulants, CYP3A4 inhibitors, NSAIDs, selective serotonin reuptake inhibitors, selective noradrenaline and serotonin reuptake inhibitors)~  * Positive results of HIV or hepatitis virology~ * Acute illness with systemic inflammatory reactions~ * Known allergies, hypersensitivities or intolerances to any of the used substances~ * Acute or recent bleeding episodes, increased risk of bleeding at the discretion of the investigator~ * History of stroke, transient ischemic attacks or intracerebral hemorrhage~ * Known coagulation or platelet disorders~ * Participation in an LPS trial within 6 weeks of the first study day~ * Severe liver or kidney dysfunction~ * Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Vorapaxar (Type: EXPERIMENTAL): subjects will be treated with 4x2,5mg vorapaxar in empty lactose-starch capsules
- Placebo (Type: PLACEBO_COMPARATOR): subjects will be treated with 4 empty lactose-starch capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CONCERTA Lab School Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ADHD diagnosis of all subtypes (except Not Otherwise Specified)~* Patients with total or subscale Attention Deficit Hyperactivity Disorder Rating Scale (ADHD RS-IV) scores \> =90th percentile relative to the general population of children by age and gender~* Patients currently receiving ADHD medication must be inadequately managed on their current stimulant dose and meet this criteria at the screening visit~* Ability to read and understand English~* Ability to attend school regularly~Exclusion Criteria:~* Estimated Full Scale IQ score of 80 or below, Severe Learning Disability~* History of or current, primary diagnosis of: severe anxiety disorder, conduct disorder, psychotic disorders, Pervasive Developmental Disorder, Eating Disorder, Obsessive-Compulsive Disorder, Sleep Disorder, Major Depressive Disorder, Bipolar Disorder, Substance Use Disorder, Chronic Tic Disorder, personal or family history of Tourette's Syndrome~* Weight \< 3rd percentile for age~* History of hospitalization for treatment of a mood, anxiety, or psychotic disorder~* History of failed response to methylphenidate

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
- 2 (Type: EXPERIMENTAL): CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males aged 18 to 50 years inclusive and body weight 65 to 100kg.~2. Subjects who are healthy as determined by pre-study medical history, physical examination, vital signs and 12 ECG.~3. Subjects whose clinical laboratory test results are normal, or where outside the reference range are judged as not clinical relevant.~Exclusion Criteria:~1. Have a history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric or allergic disease excluding mild asymptomatic seasonal allergies.~2. Subject with a psychiatric disorder or considered unsuitable for inclusion by the investigator.~3. History or current clinically significant, excluding mild asymptomatic seasonal allergies, hypersensitivity or allergic reactions including known or suspected drug hypersensitivity to any component of the study drug formulations or comparable drugs.~4. Any biological drug within 3 months or monoclonal antibodies within 9 months of study drug administration.~5. Intake of herbal remedies within 14 days prior to study drug administration.~6. History of alcohol abuse or a positive alcohol test on screening or admission to the clinical center.~7. Any persons who are:an employee of the Principal Investigator, clinical center, Clinical Research Organization (CRO) or Sponsor;a relative of an employee of the clinical center, the Investigators, CRO or the Sponsor.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- BAT1706 (Type: EXPERIMENTAL): BAT1706 injection
- EU-sourced Avastin (Type: ACTIVE_COMPARATOR): EU-sourced Avastin
- US-sourced Avastin (Type: ACTIVE_COMPARATOR): US-sourced Avastin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A PK and Safety Study in Subjects With Hepatic Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate or severe hepatic impairment or matched control~* BMI between 18.0 and 40.0 kg/m2~Exclusion Criteria:~* Evidence of acute deterioration of hepatic function within 8 weeks~* ALT or AST ≥ 5 times upper limit of normal for moderates; ALT or AST ≥ 8 times upper limit of normal for severes~* Total bilirubin \> 5 mg/dl for moderates; no upper limit for severes~* Hemoglobin \< 10g/dl for moderates; Hemoglobin \< 9g/dl for severes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Moderate hepatic (Type: EXPERIMENTAL): None
- Severe Hepatic (Type: EXPERIMENTAL): None
- Matched control (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Employment-Based Depot Naltrexone Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Individuals were eligible if they:~* met the Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition (DSM-IV) criteria for opioid dependence,~* reported using heroin on at least 21 of the last 30 days while in community,~* were unemployed,~* were aged 18-65 years,~* were medically approved for naltrexone~* lived in or near Baltimore, MD.~Individuals were excluded if they~* had current DSM-IV major Axis I disorders,~* had current suicidal or homicidal ideation,~* expressed interest in methadone treatment,~* were required to use opioids for medical purposes,~* earned more than $200 in taxable income over the previous 30 days,~* had physical limitations that would prevent them from using a keyboard,~* were pregnant or breastfeeding,~* had serum aminotransferase levels more than three times over normal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- No Intervention (Type: NO_INTERVENTION): Participants were offered depot naltrexone injections and were not required to take scheduled injections to work.
- Employment-based reinforcement (Type: EXPERIMENTAL): Participants were offered depot naltrexone injections and were required to take scheduled injections to work.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-80 years old~* Currently meet the DSM-IV-TR criteria for Major Depressive Disorder~* The patient's current depressive episode must be at least 4 weeks in duration~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control.~* Patients with a history of meeting DSM-IV-TR criteria for: a. any manic or hypomanic episode; b. schizophrenia or any other psychotic disorder; c. obsessive-compulsive disorder.~* Patients who are considered a suicide risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
- 2 (Type: PLACEBO_COMPARATOR): Matching placebo capsules, oral administration, once daily dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women.~* Biopsy confirmation of primary breast cancer.~* Oestrogen receptor positive tumour.~* Fit for surgery within one month.~* Written informed consent to participate in the study~Exclusion Criteria:~* Previous treatment with any anti-hormonal therapy for breast cancer.~* Previous radiotherapy to the primary tumour.~* Previous chemotherapy for the primary tumour.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Anastrozole Monotherapy
- 2 (Type: EXPERIMENTAL): Fulvestrant Monotherapy
- 3 (Type: EXPERIMENTAL): Anastrozole + Fulvestrant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven Small Cell Lung Cancer (SCLC)~* WHO performance status : 0, 1~Exclusion Criteria:~* No previous radiotherapy is allowed except on bone metastases when newly diagnosed. Radiotherapy is not allowed for vena cava syndrome, a stent is recommended ;~* No prior surgery on the primary tumor except for palliative purpose (stent for vena cava syndrome).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- B (Type: EXPERIMENTAL): None
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy children 12-23 months of age~Exclusion Criteria:~* Previously had measles, mumps, rubella, or varicella~* Compromised immune system

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* the diagnosis of systemic lupus erythematosus (by meeting 4 criteria of the American College of Rheumatology)~* renal biopsy documenting lupus nephritis according to the classification of the World Health Organization (WHO) or the updated International Society of Nephrology/Renal Pathology Society (ISN/RPS) as proliferative glomerulonephritis class III (focal) or IV (diffuse)~* clinical activity as defined by presence of at least two of the following:~  * abnormal proteinuria (more than 500mg of protein in in a 24-hour urine specimen)~ * abnormal microscopic hematuria, or~ * C3 hypocomplementemia (the latter two were defined according to the norms in the laboratories of the participating centers)~Exclusion Criteria:~* treatment with cyclophosphamide or cyclosporine A ever before~* treatment with other immunosuppressive drugs (such as azathioprine or mycophenolate mofetil) or high dose glucocorticoids (≥ 80mg of prednisone or methylprednisolone) within the last 3 months~* persistent elevation of serum creatinine (≥140 μmol/l)~* pregnancy or lactation~* bone marrow insufficiency with cytopenias not attributable to SLE, and 8severe coexisting conditions, such as infection, liver disease, active peptic ulcer etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cyclosporine A (Type: EXPERIMENTAL): Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months.
- Cyclophosphamide (Type: ACTIVE_COMPARATOR): Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TAK-438 - Safety, Blood Levels & Effects of Repeated Doses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects aged 18 to 45, inclusive, who are in good health, as determined by medical history, physical examination, clinical laboratory evaluations and urine drug screen.~* The subject has the ability to tolerate the pH probe for 24 hours prior to Randomization (Day 1).~Exclusion Criteria:~* Clinically significant history of hypersensitivity to any drug or food or any excipients of TAK-438~* History of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive esophagitis, duodenal ulcer,gastric ulcer, dyspepsia, Barrett's esophagus, or Zollinger-Ellison syndrome~* The subject has a positive test result for Helicobacter pylori at the Initial Screening Visit~* Any clinically significant results from physical examinations or clinical laboratory results as deemed by the investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1: TAK-438 10 mg (Type: EXPERIMENTAL): TAK-438 10 mg tablets, orally, once, daily, for 7 days.
- Cohort 2: TAK-438 20 mg (Type: EXPERIMENTAL): TAK-438 20 mg tablets, orally, once, daily, for 7 days.
- Cohort 3: TAK-438 40 mg (Type: EXPERIMENTAL): TAK-438 40 mg tablets, orally, once, daily, for 7 days.
- Cohort 4: TAK-438 30 mg (Type: EXPERIMENTAL): TAK-438 30 mg tablets, orally, once, daily, for 7 days.
- Cohorts 1-4: Placebo (Type: PLACEBO_COMPARATOR): TAK-438 placebo-matching tablets, orally, once, daily, for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TRV130 for the Treatment of Pain After Abdominoplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* \>=18 and \<=65 years of age.~* Plans to undergo an abdominoplasty procedure with no additional collateral procedures.~* Is able to understand and comply with the procedures and study requirements, and to provide written informed consent before any study procedure.~Exclusion Criteria:~* ASA Physical Status Classification System classification of P3 or worse.~* Has surgical or post-surgical complications.~* Has clinically significant medical conditions or history of such conditions that may interfere with the interpretation of efficacy, safety, or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of drugs.~* Has previously participated in another TRV130 clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TRV130 (Type: EXPERIMENTAL): None
- Morphine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Moderate-to-severe plaque psoriasis patients whom have been receiving etanercept for at least 1 year duration.~* Have difficult to treat sites at presentation.~* Age ≥18 years.~* No history of using other biological treatments, other than etanercept for the treatment of moderate-to-severe PsO.~Exclusion Criteria:~* Etanercept use for treatment of moderate-to-severe PsO less than 1 year duration.~* Previous use of another biological treatment for treatment of moderate-to-severe PsO.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with moderate to severe plaque psoriasis (Type: None): Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete